196 related articles for article (PubMed ID: 30513193)
1. Delivery of an Artificial Transcription Regulator dCas9-VPR by Extracellular Vesicles for Therapeutic Gene Activation.
Lainšček D; Kadunc L; Keber MM; Bratkovič IH; Romih R; Jerala R
ACS Synth Biol; 2018 Dec; 7(12):2715-2725. PubMed ID: 30513193
[TBL] [Abstract][Full Text] [Related]
2. CRISPR/Cas9 Genome Editing vs. Over-Expression for Fluorescent Extracellular Vesicle-Labeling: A Quantitative Analysis.
Strohmeier K; Hofmann M; Hauser F; Sivun D; Puthukodan S; Karner A; Sandner G; Le Renard PE; Jacak J; Mairhofer M
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008709
[TBL] [Abstract][Full Text] [Related]
3. Targeting cancer epigenetics with CRISPR-dCAS9: Principles and prospects.
Rahman MM; Tollefsbol TO
Methods; 2021 Mar; 187():77-91. PubMed ID: 32315755
[TBL] [Abstract][Full Text] [Related]
4. Extracellular vesicles as a potential delivery platform for CRISPR-Cas based therapy in epithelial ovarian cancer.
Godbole N; Quinn A; Carrion F; Pelosi E; Salomon C
Semin Cancer Biol; 2023 Nov; 96():64-81. PubMed ID: 37820858
[TBL] [Abstract][Full Text] [Related]
5. Hepatic stellate cell reprogramming via exosome-mediated CRISPR/dCas9-VP64 delivery.
Luo N; Li J; Chen Y; Xu Y; Wei Y; Lu J; Dong R
Drug Deliv; 2021 Dec; 28(1):10-18. PubMed ID: 33336604
[TBL] [Abstract][Full Text] [Related]
6. Engineered Cas9 extracellular vesicles as a novel gene editing tool.
Osteikoetxea X; Silva A; Lázaro-Ibáñez E; Salmond N; Shatnyeva O; Stein J; Schick J; Wren S; Lindgren J; Firth M; Madsen A; Mayr LM; Overman R; Davies R; Dekker N
J Extracell Vesicles; 2022 May; 11(5):e12225. PubMed ID: 35585651
[TBL] [Abstract][Full Text] [Related]
7. Gene Editing by Extracellular Vesicles.
Kostyushev D; Kostyusheva A; Brezgin S; Smirnov V; Volchkova E; Lukashev A; Chulanov V
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33028045
[TBL] [Abstract][Full Text] [Related]
8. Nonviral gene editing via CRISPR/Cas9 delivery by membrane-disruptive and endosomolytic helical polypeptide.
Wang HX; Song Z; Lao YH; Xu X; Gong J; Cheng D; Chakraborty S; Park JS; Li M; Huang D; Yin L; Cheng J; Leong KW
Proc Natl Acad Sci U S A; 2018 May; 115(19):4903-4908. PubMed ID: 29686087
[TBL] [Abstract][Full Text] [Related]
9. Stabilization of Foxp3 expression by CRISPR-dCas9-based epigenome editing in mouse primary T cells.
Okada M; Kanamori M; Someya K; Nakatsukasa H; Yoshimura A
Epigenetics Chromatin; 2017; 10():24. PubMed ID: 28503202
[TBL] [Abstract][Full Text] [Related]
10. Artificial Virus Delivers CRISPR-Cas9 System for Genome Editing of Cells in Mice.
Li L; Song L; Liu X; Yang X; Li X; He T; Wang N; Yang S; Yu C; Yin T; Wen Y; He Z; Wei X; Su W; Wu Q; Yao S; Gong C; Wei Y
ACS Nano; 2017 Jan; 11(1):95-111. PubMed ID: 28114767
[TBL] [Abstract][Full Text] [Related]
11. Live imaging and tracking of genome regions in CRISPR/dCas9 knock-in mice.
Duan J; Lu G; Hong Y; Hu Q; Mai X; Guo J; Si X; Wang F; Zhang Y
Genome Biol; 2018 Nov; 19(1):192. PubMed ID: 30409154
[TBL] [Abstract][Full Text] [Related]
12. New Therapeutics for Extracellular Vesicles: Delivering CRISPR for Cancer Treatment.
Yan B; Liang Y
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555398
[TBL] [Abstract][Full Text] [Related]
13. Current and prospective strategies for advancing the targeted delivery of CRISPR/Cas system via extracellular vesicles.
Huang X; Li A; Xu P; Yu Y; Li S; Hu L; Feng S
J Nanobiotechnology; 2023 Jun; 21(1):184. PubMed ID: 37291577
[TBL] [Abstract][Full Text] [Related]
14. Inducible CRISPR genome-editing tool: classifications and future trends.
Dai X; Chen X; Fang Q; Li J; Bai Z
Crit Rev Biotechnol; 2018 Jun; 38(4):573-586. PubMed ID: 28936886
[TBL] [Abstract][Full Text] [Related]
15. Reporter mice for isolating and auditing cell type-specific extracellular vesicles in vivo.
McCann JV; Bischoff SR; Zhang Y; Cowley DO; Sanchez-Gonzalez V; Daaboul GD; Dudley AC
Genesis; 2020 Jul; 58(7):e23369. PubMed ID: 32543746
[TBL] [Abstract][Full Text] [Related]
16. Extracellular vesicles engineered with valency-controlled DNA nanostructures deliver CRISPR/Cas9 system for gene therapy.
Zhuang J; Tan J; Wu C; Zhang J; Liu T; Fan C; Li J; Zhang Y
Nucleic Acids Res; 2020 Sep; 48(16):8870-8882. PubMed ID: 32810272
[TBL] [Abstract][Full Text] [Related]
17. CRISPR-assisted transcription activation by phase-separation proteins.
Liu J; Chen Y; Nong B; Luo X; Cui K; Li Z; Zhang P; Tan W; Yang Y; Ma W; Liang P; Songyang Z
Protein Cell; 2023 Dec; 14(12):874-887. PubMed ID: 36905356
[TBL] [Abstract][Full Text] [Related]
18. AAV-Mediated CRISPR/Cas Gene Editing of Retinal Cells In Vivo.
Hung SS; Chrysostomou V; Li F; Lim JK; Wang JH; Powell JE; Tu L; Daniszewski M; Lo C; Wong RC; Crowston JG; Pébay A; King AE; Bui BV; Liu GS; Hewitt AW
Invest Ophthalmol Vis Sci; 2016 Jun; 57(7):3470-6. PubMed ID: 27367513
[TBL] [Abstract][Full Text] [Related]
19.
Ye Y; Shi Q; Yang T; Xie F; Zhang X; Xu B; Fang J; Chen J; Zhang Y; Li J
Technol Cancer Res Treat; 2022; 21():15330338221085370. PubMed ID: 35315725
[No Abstract] [Full Text] [Related]
20. Waking up dormant tumor suppressor genes with zinc fingers, TALEs and the CRISPR/dCas9 system.
Garcia-Bloj B; Moses C; Sgro A; Plani-Lam J; Arooj M; Duffy C; Thiruvengadam S; Sorolla A; Rashwan R; Mancera RL; Leisewitz A; Swift-Scanlan T; Corvalan AH; Blancafort P
Oncotarget; 2016 Sep; 7(37):60535-60554. PubMed ID: 27528034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
